Literature DB >> 6254755

A controlled study of ACTH therapy in infantile spasms.

R A Hrachovy, J D Frost, P Kellaway, T Zion.   

Abstract

A controlled study of 5 patients with infantile spasms was performed to determine the effectiveness of corticotropin (ACTH) treatment. Patients were monitored serially, using a time-synchronized polygraphic and video system. Serum cortisol levels were determined by radioimmunoassay. Four patients showed total cessation of seizures and normalization of the EEG on low-dose ACTH therapy. Two of these patients became hypertensive, requiring discontinuance of ACTH. Serum cortisol levels increased markedly in all patients after initiation of ACTh therapy. There appeared to be no consistent difference in serum cortisol levels between patients receiving 20 units/day of ACTH and those receiving 30 or 40 units/day, and there was no difference in cortisol levels in those patients who became hypertensive and those who did not.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6254755     DOI: 10.1111/j.1528-1157.1980.tb04316.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  10 in total

1.  Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.

Authors:  C Y Go; M T Mackay; S K Weiss; D Stephens; T Adams-Webber; S Ashwal; O C Snead
Journal:  Neurology       Date:  2012-06-12       Impact factor: 9.910

2.  AQB-565 shows promise in preclinical testing in the model of epileptic spasms during infancy: Head-to-head comparison with ACTH.

Authors:  Chian-Ru Chern; Chian-Jiang Chern; Jana Velíšková; Libor Velíšek
Journal:  Epilepsy Res       Date:  2019-03-11       Impact factor: 3.045

3.  Infantile Spasms.

Authors:  Mary L. Zupanc
Journal:  Curr Treat Options Neurol       Date:  2001-05       Impact factor: 3.598

4.  Topiramate and adrenocorticotropic hormone (ACTH) as initial treatment for infantile spasms.

Authors:  Bradley Peltzer; William D Alonso; Brenda E Porter
Journal:  J Child Neurol       Date:  2009-02-18       Impact factor: 1.987

Review 5.  Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society.

Authors:  M T Mackay; S K Weiss; T Adams-Webber; S Ashwal; D Stephens; K Ballaban-Gill; T Z Baram; M Duchowny; D Hirtz; J M Pellock; W D Shields; S Shinnar; E Wyllie; O C Snead
Journal:  Neurology       Date:  2004-05-25       Impact factor: 9.910

6.  Response to treatment in a prospective national infantile spasms cohort.

Authors:  Kelly G Knupp; Jason Coryell; Katherine C Nickels; Nicole Ryan; Erin Leister; Tobias Loddenkemper; Zachary Grinspan; Adam L Hartman; Eric H Kossoff; William D Gaillard; John R Mytinger; Sucheta Joshi; Renée A Shellhaas; Joseph Sullivan; Dennis Dlugos; Lorie Hamikawa; Anne T Berg; John Millichap; Douglas R Nordli; Elaine Wirrell
Journal:  Ann Neurol       Date:  2016-02-13       Impact factor: 10.422

7.  Topiramate monotherapy in infantile spasm.

Authors:  Young-Se Kwon; Yong-Hoon Jun; Young-Jin Hong; Byong-Kwan Son
Journal:  Yonsei Med J       Date:  2006-08-31       Impact factor: 2.759

8.  Attention deficit associated with early life interictal spikes in a rat model is improved with ACTH.

Authors:  Amanda E Hernan; Abigail Alexander; Pierre-Pascal Lenck-Santini; Rod C Scott; Gregory L Holmes
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

Review 9.  Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications.

Authors:  Michael Philbin; John Niewoehner; George J Wan
Journal:  Adv Ther       Date:  2017-06-28       Impact factor: 3.845

10.  ACTH Prevents Deficits in Fear Extinction Associated with Early Life Seizures.

Authors:  Andrew T Massey; David K Lerner; Gregory L Holmes; Rod C Scott; Amanda E Hernan
Journal:  Front Neurol       Date:  2016-05-02       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.